Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.

ABSTRACT:

Aims

As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations.

Methods and results

Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE)-project, we analysed data of 56 804 participants from 7 prospective population-based cohorts across Europe with a maximum follow-up of 24 years. All Lp(a) measurements were performed in the centr

SUBMITTER: Waldeyer C 

PROVIDER: S-EPMC5837491 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature